The effect of antipsychotic medication and the associated hyperprolactinemia as a risk factor for periodontal diseases in schizophrenic patients: a cohort retrospective study.
Antipsychotics
Early prevention
Hyperprolactinemia
Periodontal disease
Schizophrenia
Journal
BMC oral health
ISSN: 1472-6831
Titre abrégé: BMC Oral Health
Pays: England
ID NLM: 101088684
Informations de publication
Date de publication:
24 10 2023
24 10 2023
Historique:
received:
17
04
2023
accepted:
11
09
2023
medline:
26
10
2023
pubmed:
25
10
2023
entrez:
24
10
2023
Statut:
epublish
Résumé
Periodontal disease is a major health problem that results in tooth loss and thus affects oral health, which affects quality of life. In particular, schizophrenic patients are at higher risk for periodontal disease due to several factors, including the effect of antipsychotic medications received by those patients. Accordingly, the aim of the present cohort retrospective study is to explore the effect of antipsychotics on periodontal health and the possible effect of antipsychotic-induced hyperprolactinemia as a risk factor for periodontal disease progression in schizophrenic patients. The study population consisted of three groups: Group A (n = 21): schizophrenic patients that have been taking "prolactin-inducing" antipsychotics for at least 1 year; Group B (n = 21): schizophrenic patients who have been taking "prolactin-sparing" antipsychotics for at least 1 year; and Group C (n = 22): newly diagnosed schizophrenic patients and/or patients who did not receive any psychiatric treatment for at least 1 year. The study groups underwent assessment of periodontal conditions in terms of pocket depth (PD), clinical attachment loss (CAL), gingival recession, tooth mobility, and bleeding on probing (BOP). Also, bone mineral density was evaluated using DEXA scans, and the serum prolactin level was measured by automated immunoassay. Results revealed a statistically significant difference in PD, CAL, and serum prolactin levels (P ≤ 0.001, P = 0.001, and P ≤ 0.001, respectively) among the 3 study groups. For both PD and CAL measurements, group A has shown significantly higher values than both groups B and C, whereas there was no statistically significant difference between the values of groups C and B. Concerning serum prolactin levels, group A had significantly higher values than groups B and C (P ≤ 0.001 and P ≤ 0.001 respectively). There was a statistically significant difference (P ≤ 0.001) between the 3 study groups in terms of bone mineral density. Moreover, there was a statistically significant direct relation between serum prolactin level and other parameters including clinical attachment loss, pocket depth measurements and bone mineral density. According to our results, it could be concluded that all antipsychotics contribute to the progression of periodontal disease, with a higher risk for prolactin-inducing antipsychotics. However, further long term, large sampled, interventional and controlled studies are required to reach definitive guidelines to allow clinicians properly manage this group of patients.
Sections du résumé
BACKGROUND
Periodontal disease is a major health problem that results in tooth loss and thus affects oral health, which affects quality of life. In particular, schizophrenic patients are at higher risk for periodontal disease due to several factors, including the effect of antipsychotic medications received by those patients. Accordingly, the aim of the present cohort retrospective study is to explore the effect of antipsychotics on periodontal health and the possible effect of antipsychotic-induced hyperprolactinemia as a risk factor for periodontal disease progression in schizophrenic patients.
METHODS AND OUTCOMES
The study population consisted of three groups: Group A (n = 21): schizophrenic patients that have been taking "prolactin-inducing" antipsychotics for at least 1 year; Group B (n = 21): schizophrenic patients who have been taking "prolactin-sparing" antipsychotics for at least 1 year; and Group C (n = 22): newly diagnosed schizophrenic patients and/or patients who did not receive any psychiatric treatment for at least 1 year. The study groups underwent assessment of periodontal conditions in terms of pocket depth (PD), clinical attachment loss (CAL), gingival recession, tooth mobility, and bleeding on probing (BOP). Also, bone mineral density was evaluated using DEXA scans, and the serum prolactin level was measured by automated immunoassay.
RESULTS
Results revealed a statistically significant difference in PD, CAL, and serum prolactin levels (P ≤ 0.001, P = 0.001, and P ≤ 0.001, respectively) among the 3 study groups. For both PD and CAL measurements, group A has shown significantly higher values than both groups B and C, whereas there was no statistically significant difference between the values of groups C and B. Concerning serum prolactin levels, group A had significantly higher values than groups B and C (P ≤ 0.001 and P ≤ 0.001 respectively). There was a statistically significant difference (P ≤ 0.001) between the 3 study groups in terms of bone mineral density. Moreover, there was a statistically significant direct relation between serum prolactin level and other parameters including clinical attachment loss, pocket depth measurements and bone mineral density.
CONCLUSION
According to our results, it could be concluded that all antipsychotics contribute to the progression of periodontal disease, with a higher risk for prolactin-inducing antipsychotics. However, further long term, large sampled, interventional and controlled studies are required to reach definitive guidelines to allow clinicians properly manage this group of patients.
Identifiants
pubmed: 37875841
doi: 10.1186/s12903-023-03404-1
pii: 10.1186/s12903-023-03404-1
pmc: PMC10594739
doi:
Substances chimiques
Antipsychotic Agents
0
Prolactin
9002-62-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
786Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Spec Care Dentist. 2001 Sep-Oct;21(5):182-6
pubmed: 11803642
Clin Biochem Rev. 2018 Feb;39(1):3-16
pubmed: 30072818
Nat Rev Microbiol. 2018 Dec;16(12):745-759
pubmed: 30301974
Arthritis Rheum. 2012 Aug;64(8):2624-31
pubmed: 22487938
Fogorv Sz. 2004 Jun;97(3):103-11
pubmed: 15282975
J Dent (Tehran). 2012 Fall;9(4):256-64
pubmed: 23323188
Int J Neuropsychopharmacol. 2005 Jun;8(2):195-201
pubmed: 15631645
Schizophr Res. 1999 Mar 1;35 Suppl:S75-86
pubmed: 10190228
Clin Cases Miner Bone Metab. 2009 Sep;6(3):229-33
pubmed: 22461251
Eur Neuropsychopharmacol. 2008 May;18 Suppl 2:S108-14
pubmed: 18346598
Trends Endocrinol Metab. 2012 Nov;23(11):576-81
pubmed: 22595550
Med Clin North Am. 2015 May;99(3):587-606
pubmed: 25841602
J Dent Res. 2014 Nov;93(11):1045-53
pubmed: 25261053
Am Fam Physician. 2010 Mar 1;81(5):617-22
pubmed: 20187598
J Clin Psychiatry. 2004 Nov;65(11):1491-8
pubmed: 15554761
J Periodontal Res. 2023 Apr;58(2):283-295
pubmed: 36575324
Psychiatry Res. 2002 Aug 5;111(1):11-20
pubmed: 12140115
J Periodontol. 2003 Jan;74(1):103-10
pubmed: 12593604
J Clin Periodontol. 2011 Mar;38 Suppl 11:60-84
pubmed: 21323705
J Clin Periodontol. 2017 Mar;44 Suppl 18:S94-S105
pubmed: 28266116
J Clin Periodontol. 1999 Feb;26(2):113-23
pubmed: 10048646
Periodontol 2000. 2020 Oct;84(1):215-216
pubmed: 32844419
Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:69-82
pubmed: 12650682
Oral Dis. 2011 Jul;17(5):450-61
pubmed: 21223455
Biol Psychiatry. 2023 Oct 1;94(7):561-568
pubmed: 37061079
J Am Dent Assoc. 2002 May;133(5):603-10; quiz 624-5
pubmed: 12036166
Spec Care Dentist. 1991 Sep-Oct;11(5):179-83
pubmed: 1839864
Cell. 2020 Jul 23;182(2):447-462.e14
pubmed: 32758418
Gen Hosp Psychiatry. 2011 May-Jun;33(3):253-9
pubmed: 21601722
Acta Odontol Scand. 1963 Dec;21:533-51
pubmed: 14121956
Spec Care Dentist. 2012 Sep-Oct;32(5):196-204
pubmed: 22943772
Neuropsychopharmacology. 2007 Mar;32(3):736-44
pubmed: 16794572
J Indian Soc Periodontol. 2014 Jan;18(1):69-73
pubmed: 24744548
Int J Dent Hyg. 2013 May;11(2):78-83
pubmed: 22583707
J Periodontol. 1999 Sep;70(9):982-91
pubmed: 10505800
Periodontol 2000. 2002;29:177-206
pubmed: 12102708
J Contemp Dent Pract. 2008 Jan 01;9(1):38-45
pubmed: 18176647
J Prosthet Dent. 1990 Feb;63(2):218-22
pubmed: 2304026
Psychiatry Res. 1994 Jan;51(1):1-10
pubmed: 7910974
N Engl J Med. 2003 Oct 30;349(18):1738-49
pubmed: 14585943
Indian J Dent Res. 2000 Jan-Mar;11(1):5-11
pubmed: 11307250
Int J Dent. 2014;2014:585048
pubmed: 24991214
Neuro Endocrinol Lett. 2011;32(4):428-36
pubmed: 21876517
J Periodontol. 1975 Oct;46(10):603-7
pubmed: 1058939
Periodontol 2000. 2020 Feb;82(1):42-64
pubmed: 31850623
Eur Psychiatry. 2003 May;18(3):101-5
pubmed: 12763294
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
J Clin Periodontol. 1992 Aug;19(7):492-6
pubmed: 1430285
J Clin Periodontol. 2017 May;44(5):456-462
pubmed: 28419559
Periodontol 2000. 2000 Jun;23:94-102
pubmed: 11276771
J Clin Periodontol. 2011 Mar;38 Suppl 11:114-8
pubmed: 21323708
J Virol. 2021 Oct 13;95(21):e0081721
pubmed: 34406857
Mol Med Rep. 2013 Mar;7(3):761-6
pubmed: 23292713
Drug Saf. 2004;27(14):1135-56
pubmed: 15554747
Lancet. 2005 Nov 19;366(9499):1809-20
pubmed: 16298220
J Periodontol. 2003 Mar;74(3):391-401
pubmed: 12710761
J Periodontol. 1996 Feb;67(2):93-102
pubmed: 8667142
J Periodontol. 1994 Dec;65(12):1134-8
pubmed: 7877085
Periodontol 2000. 2020 Jun;83(1):90-106
pubmed: 32385879
J Clin Psychopharmacol. 2005 Feb;25(1):26-31
pubmed: 15643097
Encephale. 2006 Jan-Feb;32(1 Pt 1):97-105
pubmed: 16633296
Swed Dent J. 2001;25(3):89-96
pubmed: 11813450
Eur J Oral Sci. 1996 Feb;104(1):10-16
pubmed: 8653490
J Periodontol. 2018 Jun;89 Suppl 1:S1-S8
pubmed: 29926946
J Dent Res. 2018 May;97(5):501-507
pubmed: 29342371
World Psychiatry. 2020 Feb;19(1):15-33
pubmed: 31922684
J Dent Res. 2000 Apr;79(4):964-9
pubmed: 10831099
Epidemiol Psychiatr Sci. 2019 Sep 17;29:e49
pubmed: 31526409
J Periodontal Res. 1997 Oct;32(7):619-25
pubmed: 9401935
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Nov;80(5):612-6
pubmed: 8556469
Periodontol 2000. 2022 Jun;89(1):9-18
pubmed: 35244969
J Gerontol A Biol Sci Med Sci. 1997 Nov;52(6):M343-51
pubmed: 9402940
Periodontol 2000. 2012 Oct;60(1):54-63
pubmed: 22909106
Cell. 2021 Jul 22;184(15):4090-4104.e15
pubmed: 34129837
Curr Osteoporos Rep. 2017 Jun;15(3):121-125
pubmed: 28432597
Curr Pharm Des. 2017;23(41):6272-6278
pubmed: 28494718
Menopause. 2017 Sep;24(9):1057-1064
pubmed: 28609384
J Periodontol. 2000 Mar;71(3):335-40
pubmed: 10776919
Int Dent J. 1975 Dec;25(4):229-35
pubmed: 1058834
Lancet. 2019 Sep 14;394(10202):939-951
pubmed: 31303314
Lancet. 2019 Jul 20;394(10194):249-260
pubmed: 31327369
Drugs. 2004;64(20):2291-314
pubmed: 15456328
J Indian Soc Periodontol. 2009 May;13(2):69-74
pubmed: 20407653
Periodontol 2000. 2013 Jun;62(1):59-94
pubmed: 23574464
Neuroendocrinology. 2011;94(3):246-54
pubmed: 21986470
Lancet Psychiatry. 2020 Jan;7(1):64-77
pubmed: 31860457
Osteoporos Int. 1999;10(1):34-40
pubmed: 10501777
Pharmacotherapy. 2009 Jan;29(1):64-73
pubmed: 19113797
J Oral Rehabil. 2019 Apr;46(4):369-376
pubmed: 30556146
J Periodontol. 2018 Jun;89 Suppl 1:S159-S172
pubmed: 29926952
Schizophr Res. 2000 Sep 1;44(3):165-75
pubmed: 10962218
Community Dent Health. 2011 Mar;28(1):69-74
pubmed: 21485239